PI3K signaling: a crossroads of metabolic regulation

References

• Foukas LC, Claret M, Pearce W et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature441(7091), 366–370 (2006).
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110[α] in insulin signaling. Cell125(4), 733–747 (2006).
   PubMed Web of Science ®Google Scholar
• Pirola L, Zvelebil MJ, Bulgarelli-Leva G et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα ). Functions of lipid kinase-deficient PI3Kα in signaling. J. Biol. Chem.276(24), 21544–21554 (2001).
   PubMedGoogle Scholar
• Ciraolo E, Iezzi M, Marone R et al. Phosphoinositide 3-kinase p110{β} activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal.1(36), RA3 (2008).
   PubMed Web of Science ®Google Scholar
• Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl Acad. Sci. USA105(24), 8292–8297 (2008).
   PubMed Web of Science ®Google Scholar
• Braccini L, Morello F, Perino A, Hirsch E. Post-wortmannin era: novel phosphoinositide 3-kinase inhibitors with potential therapeutic applications. Curr. Enzyme Inhibition (2009) (In Press).
   PubMedGoogle Scholar
• Iida S, Ono A, Sayama K et al. Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/MMAC1 gene. Anticancer Res.20(3B), 1901–1904 (2000).
   PubMedGoogle Scholar
• Ooms LM, Horan KA, Rahman P et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem. J.419(1), 29–49 (2009).
   PubMed Web of Science ®Google Scholar
• Kaisaki PJ, Delepine M, Woon PY et al. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes53(7), 1900–1904 (2004).
   PubMedGoogle Scholar
• Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. Two new substrates in insulin signaling IRS5/DOK4 and IRS6/DOK5. J. Biol. Chem.278(28), 25323–25330 (2003).
   PubMed Web of Science ®Google Scholar
• Sun XJ, Pons S, Wang LM et al. The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol. Endocrinol.11(2), 251–262 (1997).
   PubMed Web of Science ®Google Scholar
• Araki E, Sun XJ, Haag BL 3rd et al. Human skeletal muscle insulin receptor substrate-1. Characterization of the cDNA, gene, and chromosomal localization. Diabetes42(7), 1041–1054 (1993).
   PubMed Web of Science ®Google Scholar
• Sciacchitano S, Taylor SI. Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene. Endocrinology138(11), 4931–4940 (1997).
   PubMedGoogle Scholar
• Schreyer S, Ledwig D, Rakatzi I, Kloting I, Eckel J. Insulin receptor substrate-4 is expressed in muscle tissue without acting as a substrate for the insulin receptor. Endocrinology144(4), 1211–1218 (2003).
   PubMedGoogle Scholar
• Alessi DR, Downes CP The role of PI 3-kinase in insulin action. Biochim. Biophys. Acta1436(1–2), 151–164 (1998).
   PubMed Web of Science ®Google Scholar
• Asano T, Kanda A, Katagiri H et al. p110β is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J. Biol. Chem.275(23), 17671–17676 (2000).
   PubMed Web of Science ®Google Scholar
• Beeson M, Sajan MP, Dizon M et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes52(8), 1926–1934 (2003).
   PubMedGoogle Scholar
• Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am. J. Physiol. Endocrinol. Metab.295(1), E29–E37 (2008).
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature378(6559), 785–789 (1995).
   PubMed Web of Science ®Google Scholar
• McManus EJ, Sakamoto K, Armit LJ et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J.24(8), 1571–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Lee AD, Hansen PA, Holloszy JO. Wortmannin inhibits insulin-stimulated but not contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett.361(1), 51–54 (1995).
   PubMed Web of Science ®Google Scholar
• Shepherd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem. J.305(Pt 1), 25–28 (1995).
   PubMed Web of Science ®Google Scholar
• Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome13(3), 169–172 (2002).
   PubMed Web of Science ®Google Scholar
• Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem.274(16), 10963–10968 (1999).
   PubMed Web of Science ®Google Scholar
• Wang Q, Bilan PJ, Tsakiridis T, Hinek A, Klip A. Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3–L1 adipocytes. Biochem. J.331(Pt 3), 917–928 (1998).
   PubMed Web of Science ®Google Scholar
• Jia S, Liu Z, Zhang S et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature454(7205), 776–779 (2008).
   PubMed Web of Science ®Google Scholar
• Maffucci T, Brancaccio A, Piccolo E, Stein RC, Falasca M. Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J.22(16), 4178–4189 (2003).
   PubMed Web of Science ®Google Scholar
• Chaussade C, Pirola L, Bonnafous S et al. Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol. Endocrinol.17(12), 2448–2460 (2003).
   PubMed Web of Science ®Google Scholar
• Domin J, Pages F, Volinia S et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J.326(Pt 1), 139–147 (1997).
   PubMed Web of Science ®Google Scholar
• Arcaro A, Volinia S, Zvelebil MJ et al. Human phosphoinositide 3-kinase C2β, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem.273(49), 33082–33090 (1998).
   PubMed Web of Science ®Google Scholar
• Ono F, Nakagawa T, Saito S et al. A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J. Biol. Chem.273(13), 7731–7736 (1998).
   PubMedGoogle Scholar
• Brown RA, Domin J, Arcaro A, Waterfield MD, Shepherd PR. Insulin activates the a isoform of class II phosphoinositide 3-kinase. J. Biol. Chem.274(21), 14529–14532 (1999).
   PubMed Web of Science ®Google Scholar
• Brown RA, Shepherd PR. Growth factor regulation of the novel class II phosphoinositide 3-kinases. Biochem. Soc. Trans.29(Pt 4), 535–537 (2001).
   PubMed Web of Science ®Google Scholar
• Arcaro A, Zvelebil MJ, Wallasch C et al. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol.20(11), 3817–3830 (2000).
   PubMed Web of Science ®Google Scholar
• Falasca M, Hughes WE, Dominguez V et al. The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem.282(38), 28226–28236 (2007).
   PubMed Web of Science ®Google Scholar
• Christoforidis S, Miaczynska M, Ashman K et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol.1(4), 249–252 (1999).
   PubMed Web of Science ®Google Scholar
• Soos MA, Jensen J, Brown RA et al. Class II phosphoinositide 3-kinase is activated by insulin but not by contraction in skeletal muscle. Arch. Biochem. Biophys.396(2), 244–248 (2001).
   PubMed Web of Science ®Google Scholar
• Daimon M, Sato H, Oizumi T et al. Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population. Biochem. Biophys. Res. Commun.365(3), 466–471 (2008).
   PubMedGoogle Scholar
• Berwick DC, Dell GC, Welsh GI et al. Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. J. Cell Sci.117(Pt 25), 5985–5993 (2004).
   PubMed Web of Science ®Google Scholar
• Ikonomov OC, Sbrissa D, Shisheva A. YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns (3,5)P2 synthesis, halts glucose entry by insulin in adipocytes. Biochem. Biophys. Res. Commun.382(3), 566–570 (2009).
   PubMed Web of Science ®Google Scholar
• Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. β-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord.9(4), 329–343 (2008).
   PubMed Web of Science ®Google Scholar
• Fruman DA, Mauvais-Jarvis F, Pollard DA et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 α. Nat. Genet.26(3), 379–382 (2000).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science307(5712), 1098–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Pende M, Kozma SC, Jaquet M et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature408(6815), 994–997 (2000).
   PubMed Web of Science ®Google Scholar
• Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA98(20), 11598–11603 (2001).
   PubMed Web of Science ®Google Scholar
• Dickson LM, Rhodes CJ. Pancreatic β-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am. J. Physiol. Endocrinol. Metab.287(2), E192–E198 (2004).
   PubMed Web of Science ®Google Scholar
• Withers DJ, Gutierrez JS, Towery H et al. Disruption of IRS-2 causes Type 2 diabetes in mice. Nature391(6670), 900–904 (1998).
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Kadowaki T, Tobe K et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature372(6502), 182–186 (1994).
   PubMed Web of Science ®Google Scholar
• Araki E, Lipes MA, Patti ME et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature372(6502), 186–190 (1994).
   PubMed Web of Science ®Google Scholar
• Laustsen PG, Michael MD, Crute BE et al. Lipoatrophic diabetes in Irs1-/-/Irs3-/- double knockout mice. Genes Dev.16(24), 3213–3222 (2002).
   PubMed Web of Science ®Google Scholar
• Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J. Clin. Invest.97(11), 2569–2575 (1996).
   PubMed Web of Science ®Google Scholar
• Um SH, D’Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab.3(6), 393–402 (2006).
   PubMed Web of Science ®Google Scholar
• Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol.25(5), 1596–1607 (2005).
   PubMedGoogle Scholar
• Chaussade C, Rewcastle GW, Kendall JD et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J.404(3), 449–458 (2007).
   PubMedGoogle Scholar
• Le Stunff C, Dechartres A, Mariot V et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes57(2), 494–502 (2008).
   PubMedGoogle Scholar
• Ozanne SE, Jensen CB, Tingey KJ et al. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia48(3), 547–552 (2005).
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Tsuji Y, Satoh S et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 α subunit of phosphoinositide 3-kinase. Nat. Genet.21(2), 230–235 (1999).
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Ueki K, Fruman DA et al. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J. Clin. Invest.109(1), 141–149 (2002).
   PubMed Web of Science ®Google Scholar
• Chen D, Mauvais-Jarvis F, Bluher M et al. p50α/p55α phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell. Biol.24(1), 320–329 (2004).
   PubMedGoogle Scholar
• Ueki K, Fruman DA, Yballe CM et al. Positive and negative roles of p85 α and p85 β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J. Biol. Chem.278(48), 48453–48466 (2003).
   PubMedGoogle Scholar
• Ueki K, Yballe CM, Brachmann SM et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA99(1), 419–424 (2002).
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Tran TT, Kondo T et al. Phosphoinositide 3-kinase regulatory subunit p85α suppresses insulin action via positive regulation of PTEN. Proc. Natl Acad. Sci. USA103(32), 12093–12097 (2006).
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Kondo T, Sajan M et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCl/z. Cell Metab.3(5), 343–353 (2006).
   PubMed Web of Science ®Google Scholar
• Kurlawalla-Martinez C, Stiles B, Wang Y et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol. Cell. Biol.25(6), 2498–2510 (2005).
   PubMed Web of Science ®Google Scholar
• Ueki K, Fruman DA, Brachmann SM et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol.22(3), 965–977 (2002).
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes54(8), 2351–2359 (2005).
   PubMed Web of Science ®Google Scholar
• Baynes KC, Beeton CA, Panayotou G et al. Natural variants of human p85 α phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. Diabetologia43(3), 321–331 (2000).
   PubMedGoogle Scholar
• George S, Rochford JJ, Wolfrum C et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science304(5675), 1325–1328 (2004).
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science292(5522), 1728–1731 (2001).
   PubMed Web of Science ®Google Scholar
• Garofalo RS, Orena SJ, Rafidi K et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β. J. Clin. Invest.112(2), 197–208 (2003).
   PubMed Web of Science ®Google Scholar
• Sun S-Y, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res.65(16), 7052–7058 (2005).
   PubMed Web of Science ®Google Scholar